A Phase I, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Categories (click each to see list of all clinical trials associated with that category): FPBCC CTO Studies, GU (ONC), Lymphoma/CLL (ONC)
Current Status: Not open
Phase: I
Principal Investigator: Teply, Benjamin
Contact Information:
Abbie Escalera
aescalera@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT07195916?term=NCT07195916&rank=1&tab=study#participation-criteria
Summary
Primary Objective: To evaluate the safety and tolerability of INCA036873.
Secondary Objectives: -To evaluate the PK of INCA036873. -To evaluate the preliminary efficacy of INCA036873.
Exploratory Objectives: -To assess the immunogenicity of INCA036873. -To evaluate baseline CD70 expression in tumor and its correlation with clinical safety and efficacy. -To evaluate pharmacodynamic biomarkers of INCA036873. -To examine the MoA of INCA036873